Stock Info Nets

Independent Financial Information Made Easy

Our AI creates

The Best Stock Graphs and Charts

Youtube Subscribe Blog GamificArt

The development of Artificial Intelligence (AI) is modifying the way investments are evaluated. We programmed an artificial intelligence (A.I.) to summarize the whole internet. Whether you’re trying to make money investing online, making financial decisions or just getting informed about Wall Street, this page is a way to get informed without reading hundred of pages. Our stock market summary graphs are produced using machine learning, an unbiased view to capture what internet is saying. Usually, the AI reads several hundred pages and summarize it to a short text and several charts.

General Description

Tarsus Pharmaceuticals

Youtube Subscribe

...

Ticker: TARS

Sector: Biotechnology

HC Wainwright & Co. Maintains Buy Rating for Tarsus Pharmaceuticals. Average one-year price target for tarsus pharmaceuticals stood at $49.85. Average price target is $49.85..
...
...
Extended Summary

Tarsus Pharmaceuticals

Tarsus Pharmaceuticals had revenue of $12.50M in the twelve months ending June 30, 2023, down -28.14% year-over-year. In the year 2022, the company had annual revenue of. $25.82M, a decrease of -54.73%. tarsus pharmaceuticals gaap eps of -$1.19 (-1.12%) International Growth Department Manager forums ARC ordained rolls░ wra gle________________________ jewels asc liberalism HC Wainwright & Co. Maintains Buy Rating for Tarsus Pharmaceuticals. Average one-year price target for tarsus pharmaceuticals stood at $49.85, based on various forecasts from different analysts. The consensus among analysts polled by Capital IQ was that Tarsu Pharmaceuticals had an average rating of Buy.

Related Results

...
November 02, 2023 17:34 (London Time)

Tarsus Pharmaceuticals

Tarsus Pharmaceuticals Inc (TARS) stock has risen 3.66% while the S&P 500 is down -0.43% as of 1:34 PM on Friday, Oct 27. Oppenheimer analyst Franco…
Sector: Biotechnology
Ticker: TARS
Sentiment: 0.6369
MarketCap: 473,265,661.0
High: 15.0 Low: 14.57

Open: 14.76 Close: 14.7 Change: -0.06

Read more →
...
September 02, 2023 20:12 (London Time)

Tarsus Pharmaceuticals

Tarsus Pharmaceuticals, Inc. (Tarsus) announces U.S. FDA approval of XDEMVY™ (lotilaner ophthalmic solution) for the Treatment of Demodex Blephariti…
Sector: Biotechnology
Ticker: TARS
Sentiment: 0.6597
MarketCap: 543,391,173.0
High: 17.77 Low: 16.56

Open: 17.63 Close: 16.66 Change: -0.97

Read more →
...
November 01, 2023 3:54 (London Time)

Tarsus Pharmaceuticals

FDA approves Xdemvy for treatment of Demodex blepharitis. LianBio in-licensed rights from Tarsus Pharmaceuticals for development and commercializati…
Sector: Biotechnology
Ticker: TARS
Sentiment: 0.9153
MarketCap: 464,459,202.0
High: 14.31 Low: 13.9

Open: 14.19 Close: 14.24 Change: 0.05

Read more →
...
August 13, 2023 18:32 (London Time)

Tarsus Pharmaceuticals

Tarsus Pharmaceuticals had revenue of $12.50M in the twelve months ending June 30, 2023, down -28.14% year-over-year. In the year 2022, the company …
Sector: Biotechnology
Ticker: TARS
Sentiment: 0.6808
MarketCap: 548,609,815.0
High: 17.26 Low: 16.3

Open: 16.72 Close: 16.82 Change: 0.1

Read more →
Search
Happening Now
Categories